精華生醫7806.TW Overview
TW StockFoods
(No presentation for 7806)
精華生醫（7806）Overall Performance
精華生醫（7806）AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
Browsing restrictions can be lifted for a fee.
The most recent financial report for 精華生醫 (7806) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7806's short-term business performance and financial health. For the latest updates on 7806's earnings releases, visit this page regularly.
According to historical valuation range analysis, 精華生醫 (7806)'s current price-to-earnings (P/E) ratio is 15.63, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 精華生醫 (7806) reported an Operating Profit of 62.6M with an Operating Margin of 22.03% this period, representing a growth of 37.2% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 精華生醫 (7806) announced revenue of 284.19M, with a Year-Over-Year growth rate of 34.83%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 精華生醫 (7806) held Total Cash and Cash Equivalents of 72.97M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 精華生醫 (7806) achieved the “three margins increasing” benchmark, with a gross margin of 33.62%%, operating margin of 22.03%%, and net margin of 16.86%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7806's profit trajectory and future growth potential.
According to the past four quarterly reports, 精華生醫 (7806)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
精華生醫 (7806)'s Free Cash Flow (FCF) for the period is 24.49M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 92.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
7806
精華生醫
0.89%
(0.01)